Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) FCF Margin: 2014-2025

Historic FCF Margin for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -217.21%.

  • ImmunityBio's FCF Margin rose 142944.00% to -217.21% in Q3 2025 from the same period last year, while for Sep 2025 it was -393.43%, marking a year-over-year increase of 552712.00%. This contributed to the annual value of -2,700.06% for FY2024, which is 6118113.00% up from last year.
  • According to the latest figures from Q3 2025, ImmunityBio's FCF Margin is -217.21%, which was up 29.03% from -306.06% recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's FCF Margin peaked at -217.21% during Q3 2025, and registered a low of -730,550.00% during Q1 2022.
  • Moreover, its 3-year median value for FCF Margin was -9,738.59% (2024), whereas its average is -64,078.07%.
  • Per our database at Business Quant, ImmunityBio's FCF Margin crashed by 68,195,144bps in 2022 and then skyrocketed by 70,184,361bps in 2023.
  • ImmunityBio's FCF Margin (Quarterly) stood at -21,036.41% in 2021, then plummeted by 12,918,003bps to -150,216.44% in 2022, then skyrocketed by 6,156,464bps to -88,651.80% in 2023, then soared by 8,749,641bps to -1,155.39% in 2024, then soared by 142,944bps to -217.21% in 2025.
  • Its last three reported values are -217.21% in Q3 2025, -306.06% for Q2 2025, and -526.89% during Q1 2025.